{"id":387988,"date":"2026-01-24T13:00:11","date_gmt":"2026-01-24T13:00:11","guid":{"rendered":"https:\/\/www.newsbeep.com\/uk\/387988\/"},"modified":"2026-01-24T13:00:11","modified_gmt":"2026-01-24T13:00:11","slug":"thousands-of-men-with-prostate-cancer-to-benefit-from-life-extending-drug-that-can-be-taken-at-home","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/uk\/387988\/","title":{"rendered":"Thousands of men with prostate cancer to benefit from life extending drug that can be taken at home"},"content":{"rendered":"

By PERKIN AMALARAJ, FOREIGN NEWS REPORTER<\/a> <\/p>\n

Published: 19:12 EST, 23 January 2026 | Updated: 19:13 EST, 23 January 2026 <\/p>\n

Thousands of men with advanced prostate cancer<\/a> in England are set to benefit from a life-extending drug that can be taken at home after it was given the go-ahead for NHS<\/a> use.<\/p>\n

Talazoparib, also known as Talzenna and made by Pfizer<\/a>, is a once-daily pill that has been recommended for people whose cancer has spread by the National Institute for Health and Care Excellence (Nice).<\/p>\n

It should be taken alongside enzalutamide – another pill which blocks the effect of the hormone testosterone on prostate cancer cells – and is suitable for patients who cannot have chemotherapy, or cannot tolerate other standard treatments.<\/p>\n

The move has been hailed as a ‘real lifeline’ for men with the disease.<\/p>\n

Talazoparib works by blocking certain enzymes from repairing damaged DNA in cancer cells, causing them to eventually die.<\/p>\n

Trials have shown that people taking the drug with enzalutamide lived almost nine months longer, and also had more time before their cancer got worse.<\/p>\n

Nice estimates that about 2,400 people in England are eligible for the drug, which is available on the NHS from today.<\/p>\n

Helen Knight, director of medicines evaluation at Nice, said: ‘We are continuing to focus on what matters most to people by recommending this effective treatment that can make a huge difference to the lives of people with advanced prostate cancer.<\/p>\n

\"Thousands <\/p>\n

Thousands of men with advanced prostate cancer in England are set to benefit from a life-extending drug that can be taken at home after it was given the go-ahead for NHS use (FIle image)<\/p>\n

‘Talazoparib plus enzalutamide can be taken at home, so provides a convenient and flexible treatment option for people who can’t have chemotherapy and are not able to take other medicines so have limited treatment options.’<\/p>\n

The recommendation from Nice comes days after new analysis found that prostate cancer is now the most common cancer in the UK.<\/p>\n

Prostate Cancer UK found that 64,425 men were diagnosed with the disease in 2022, compared with 61,640 people with breast cancer, which had previously been the most common cancer.<\/p>\n

The figures are a 24% rise on the previous year when 51,823 men were diagnosed with the disease.<\/p>\n

Prostate cancer officially became the most common cancer in England a year ago, but new figures from Scotland, with data from Wales and Northern Ireland, enabled the UK-wide figure.<\/p>\n

Amy Rylance, assistant director of health improvement at Prostate Cancer UK, said: ‘When hormone therapy stops working for a man with advanced prostate cancer, who is unable to have chemotherapy, it can be hugely distressing.<\/p>\n

‘Their treatment options become more limited, and they face a lot of uncertainty.<\/p>\n

‘That’s why the fact this treatment is now approved is so exciting.<\/p>\n

‘For these men, having talazoparib approved is a real lifeline, and research shows that men who receive talazoparib alongside enzalutamide get almost nine months more of life with their loved ones than men just on enzalutamide.<\/p>\n

‘We know that for men with some genetic variations, like BRCA and HRR, the treatment can be even more effective.’<\/p>\n

Share or comment on this article:
\n Thousands of men with prostate cancer to benefit from life extending drug that can be taken at home<\/p>\n","protected":false},"excerpt":{"rendered":"By PERKIN AMALARAJ, FOREIGN NEWS REPORTER Published: 19:12 EST, 23 January 2026 | Updated: 19:13 EST, 23 January…\n","protected":false},"author":2,"featured_media":387989,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[97,309,59,102,104,7183,56,54,55],"class_list":["post-387988","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-dailymail","tag-england","tag-gb","tag-health","tag-nhs","tag-pfizer","tag-uk","tag-united-kingdom","tag-unitedkingdom"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/387988","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/comments?post=387988"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/387988\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media\/387989"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media?parent=387988"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/categories?post=387988"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/tags?post=387988"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}